MAIA Biotechnology, Inc. (MAIA) News
Track canonical SquawkNews coverage tagged to MAIA, MAIA Biotechnology, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 10 indexed stories across 7 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
MAIA Biotechnology (MAIA) Expands Phase 3 THIO-104 Trial to Spain and Portugal
MAIA Biotechnology received approvals in Spain and Portugal to begin screening for its pivotal Phase 3 THIO-104 NSCLC trial, targeting ~100 patients dosed by year-end 2026 and an interim survival analysis expected in 202
NEWS | Sep 23, 2026, 01:23 PM UTC
L
MAIA - MAIA Biotechnology Expands Pivotal Phase 3 THIO-104 Non-Small Cell Lung Cancer Trial into Spain and Portugal
MAIA - MAIA Biotechnology Expands Pivotal Phase 3 THIO-104 Non-Small Cell Lung Cancer Trial into Spain and Portugal
NEWS | Sep 23, 2026, 01:17 PM UTC
L
MAIA - MAIA Biotechnology Reports Pivotal Phase 3 Clinical Trial Progress in Advanced Non-Small Cell Lung Cancer
MAIA - MAIA Biotechnology Reports Pivotal Phase 3 Clinical Trial Progress in Advanced Non-Small Cell Lung Cancer
NEWS | Sep 22, 2026, 12:52 PM UTC
L
MAIA - MAIA Biotechnology Doses First U.S. Patient in Ongoing Phase 2 Non-Small Cell Lung Cancer Clinical Trial
MAIA - MAIA Biotechnology Doses First U.S. Patient in Ongoing Phase 2 Non-Small Cell Lung Cancer Clinical Trial
NEWS | Sep 16, 2026, 12:22 PM UTC
L
MAIA Biotechnology, Inc. (AMEX:MAIA) Discloses Insider Share Purchases
Board member Ramiro Guerrero bought 185,078 shares for about $252,284 at $1.36 avg. CEO Vlad Vitoc bought 73,000 shares at $1.37 avg. Directors and officers now hold 21.34% as of Sept. 14, 2026.Material DetailsContext by
EQUITY | Sep 15, 2026, 12:21 PM UTC
L
MAIA Biotechnology Announces Open Market Purchases of Company Stock by Long-Standing Board Member and CEO
CHICAGO, Sept. 15, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer, today annou
EQUITY | Sep 15, 2026, 12:15 PM UTC
L
MAIA - MAIA Biotechnology Delivers Oral and Poster Presentations Showcasing Next-Generation Telomere-Targeting Cancer Therapies at IRT 2026
MAIA - MAIA Biotechnology Delivers Oral and Poster Presentations Showcasing Next-Generation Telomere-Targeting Cancer Therapies at IRT 2026
EQUITY | Sep 10, 2026, 12:15 PM UTC
L
MAIA files $150 million mixed shelf registration
MAIA files a Form S-3 for a $150,000,000 mixed shelf registration, allowing it to issue or sell securities under the shelf statement.
REGULATION | Aug 21, 2026, 08:17 PM UTC
M
MAIA files to offer securities up to $150 million
MAIA files an SEC registration indicating it may offer securities up to $150 million, with no catalyst or timing detail supplied in the alert.
MNA | Aug 21, 2026, 08:16 PM UTC
L
MAIA Completes Enrollment
MAIA Biotechnology completes international enrollment in Part C of Phase 2 THIO-101 expansion trial in third-line non-small cell lung cancer
EQUITY | Jun 25, 2026, 12:08 PM UTC